Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: A post hoc analysis

Journal of Clinical Psychiatry

Volumn 76, Issue 6, 2015, Pages 728-734

  Berk, Michael ^a,b   Tiller, John W G ^b   Zhao, Jun ^c   Yatham, Lakshmi N ^d   Malhi, Gin S ^e   Weiller, Emmanuelle ^f  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF SYDNEY   (Australia)

^f H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; OLANZAPINE; PLACEBO; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; AGED; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; CONTROLLED STUDY; CONTUSION; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; EVENING DOSAGE; FEMALE; HUMAN; HYPESTHESIA; INCREASED APPETITE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; PAIN; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SHORT FORM 36; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; YOUNG MANIA RATING SCALE; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84932637973     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08827     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537. doi:10.1001/archpsyc.59.6.530 PubMed
3. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64(6):680-690, quiz 738-739. doi:10.4088/JCP.v64n0610 PubMed
4. Yatham LN, Lecrubier Y, Fieve RR, et al. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord. 2004;6(5):379-385. doi:10.1111/j.1399-5618.2004.00134.x PubMed
5. Leverich GS, Altshuler LL, Frye MA, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry. 2003;64(5):506-515. doi:10.4088/JCP.v64n0503 PubMed
6. Sato T, Bottlender R, Schröter A, et al. Frequency of manic symptoms during a depressive episode and unipolar 'depressive mixed state' as bipolar spectrum. Acta Psychiatr Scand. 2003;107(4):268-274. doi:10.1034/j.1600-0447.2003.00051.x PubMed
7. Malhi GS, Bargh DM, Kuiper S, et al. Modeling bipolar disorder suicidality. Bipolar Disord. 2013;15(5):559-574. doi:10.1111/bdi.12093 PubMed
8. Berk M, Berk L, Dodd S, et al. The sick role, illness cognitions and outcomes in bipolar disorder. J Affect Disord. 2013;146(1):146-149. doi:10.1016/j.jad.2012.07.003 PubMed
9. Stange JP, Sylvia LG, da Silva Magalhães PV, et al. Extreme attributions predict the course of bipolar depression: results from the STEP-BD randomized controlled trial of psychosocial treatment. J Clin Psychiatry. 2013;74(3):249-255. doi:10.4088/JCP.12m08019 PubMed
10. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience. 2009;164(1):331-343. doi:10.1016/j.neuroscience.2009.03.080 PubMed
11. Lagerberg TV, Sundet K, Aminoff SR, et al. Excessive cannabis use is associated with earlier age at onset in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2011;261(6):397-405. doi:10.1007/s00406-011-0188-4 PubMed
12. Larsson S, Aas M, Klungsøyr O, et al. Patterns of childhood adverse events are associated with clinical characteristics of bipolar disorder. BMC Psychiatry. 2013;13(1):97. doi:10.1186/1471-244X-13-97 PubMed
13. Price AL, Marzani-Nissen GR. Bipolar disorders: a review. Am Fam Physician. 2012;85(5):483-493. PubMed
14. Martínez-Arán A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry. 2004;161(2):262-270. doi:10.1176/appi.ajp.161.2.262 PubMed
15. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003;60(4):402-407. doi:10.1001/archpsyc.60.4.402 PubMed
16. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44. doi:10.1111/bdi.12025 PubMed
17. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906-912. doi:10.1176/appi.ajp.158.6.906 PubMed
18. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722. doi:10.1056/NEJMoa064135 PubMed
19. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088. doi:10.1001/archpsyc.60.11.1079 PubMed
20. Lombardo I, Sachs G, Kolluri S, et al. Two 6-week, randomized, doubleblind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol. 2012;32(4):470-478. doi:10.1097/JCP.0b013e31825ccde5 PubMed
21. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebocontrolled studies. J Clin Psychopharmacol. 2008;28(1):13-20. doi:10.1097/jcp.0b013e3181618eb4 PubMed
22. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebocontrolled study. Am J Psychiatry. 2014;171(2):160-168. doi:10.1176/appi.ajp.2013.13070984 PubMed
23. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169-177. doi:10.1176/appi.ajp.2013.13070985 PubMed
24. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73(1-2):123-131. doi:10.1016/S0165-0327(02)00332-4 PubMed
25. Berk M, Berk L, Davey CG, et al. Treatment of bipolar depression. MJA Open. 2012;1(suppl 4):32-35.
26. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673-686. doi:10.1111/j.1399-5618.2009.00748.x PubMed
27. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1-2):27-38. doi:10.1016/j.jad.2009.12.028 PubMed
28. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.1192/bjp.133.5.429 PubMed
29. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
30. Montgomery SM. Depressive symptoms in acute schizophrenia. Prog Neuropsychopharmacol. 1979;3(4):429-433. doi:10.1016/0364-7722(79)90058-4 PubMed
31. Müller-Thomsen T, Arlt S, Mann U, et al. Detecting depression in Alzheimer's disease: evaluation of four different scales. Arch Clin Neuropsychol. 2005;20(2):271-276. doi:10.1016/j.acn.2004.03.010 PubMed
32. Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a doubleblind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609. doi:10.1097/01.jcp.0000248603.76231.b7 PubMed
33. Malhi GS, Bargh DM, McIntyre R, et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord. 2012;14(suppl 2):1-21. doi:10.1111/j.1399-5618.2012.00989.x PubMed
34. Grossini E, Gramaglia C, Farruggio S, et al. Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation. Vascul Pharmacol. 2014;60(3):127-141. doi:10.1016/j.vph.2014.01.008 PubMed